GlassScriptPhysician profile
Atman U Shah
NPI 1023219698
$16,351.95
in general payments reported to CMS, 2019-2025
62 companies · $11K in 2025
The $11K reported for 2025 was more than what 81% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193 · 2020: $82.57 · 2021: $910 · 2022: $918 · 2023: $1,730 · 2024: $1,956 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,310 · Consulting Fee: $3,300 · Travel and Lodging: $2,610 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,757 · Education: $273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,309.72 |
| Consulting Fee | $3,300.00 |
| Travel and Lodging | $2,609.64 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,757.15 |
| Education | $272.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $7,262.96 | 2025 | Navitor |
| E.R. Squibb & Sons, L.L.C. | $929.44 | 2019-2025 | Opdivo, Reblozyl, Opdualag |
| Novartis Pharmaceuticals Corporation | $571.49 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $464.36 | 2019-2025 | Imfinzi, Enhertu, Lynparza |
| Regeneron Healthcare Solutions, INC. | $426.69 | 2020-2025 | Libtayo |
| Janssen Biotech, INC. | $403.42 | 2022-2025 | Rybrevant, Carvykti, Darzalex |
| Genentech USA, INC. | $361.03 | 2022-2025 | Lunsumio, Polivy, Tecentriq |
| Galvanize Therapeutics, INC | $352.46 | 2023-2025 | Aliya System |
| Glaxosmithkline, LLC. | $322.86 | 2021-2025 | Ojjaara, Jemperli, Zejula |
| Daiichi Sankyo INC. | $318.81 | 2024-2025 | Enhertu, Datroway, Injectafer |
| Pfizer INC. | $300.73 | 2023-2025 | |
| Edwards Lifesciences Corporation | $296.68 | 2025 | |
| Gilead Sciences, INC. | $263.83 | 2021-2025 | Trodelvy |
| Abbvie INC. | $241.65 | 2022-2025 | Venclexta |
| Lilly USA, LLC | $241.26 | 2021-2025 |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $214.69 | 2024-2025 | Tecentriq, Tecentriq Hybreza, Alecensa |
| Medtronic, INC. | $195.88 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $189.30 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Beigene USA, INC. | $185.91 | 2021-2023 | Brukinsa |
| Eisai INC. | $170.77 | 2021-2025 | |
| Genzyme Corporation | $168.23 | 2022-2025 | |
| Celgene Corporation | $161.18 | 2022-2025 | Reblozyl |
| Amgen INC. | $151.89 | 2020-2024 | Prolia, Lumakras |
| Foundation Medicine, INC. | $147.23 | 2023 | |
| Caris Mpi, INC. | $145.98 | 2025 | Mi Cancer Seek |
| Tempus Ai, INC | $141.43 | 2025 | Xt Cdx |
| Aveo Pharmaceuticals, INC. | $137.25 | 2022-2023 | Fotivda |
| Janssen Scientific Affairs, LLC | $115.55 | 2024-2025 | Tecvayli, Talvey, Darzalex |
| Incyte Corporation | $112.23 | 2023-2025 | Jakafi, Monjuvi |
| Kite Pharma, INC. | $105.63 | 2020-2023 | |
| Genmab U.S., INC. | $104.45 | 2022-2025 | Tivdak |
| Array Biopharma INC | $84.99 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Exelixis INC. | $76.07 | 2024-2025 | Cabometyx |
| Pharmacosmos Therapeutics INC. | $70.64 | 2024-2025 | Monoferric, Cosela |
| Bayer Healthcare Pharmaceuticals INC. | $70.16 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.82 | 2024-2025 | Gilotrif |
| Springworks Therapeutics, INC. | $58.81 | 2024-2025 | Ogsiveo |
| Dendreon Pharmaceuticals LLC | $57.81 | 2025 | Provenge |
| Stemline Therapeutics INC. | $54.42 | 2023-2024 | Orserdu |
| Astellas Pharma US INC | $48.77 | 2022-2025 | Vyloy |
| Sobi, INC | $47.56 | 2023-2024 | |
| Sumitomo Pharma America, INC. | $46.93 | 2024 | Orgovyx |
| Pharmaessentia USA Corporation | $46.51 | 2023-2025 | Besremi |
| Blueprint Medicines Corporation | $37.13 | 2022-2025 | Ayvakit |
| Jazz Pharmaceuticals INC. | $34.27 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.20 | 2025 | Iclusig |
| Beone Medicines USA, INC. | $31.88 | 2025 | Brukinsa |
| Karyopharm Therapeutics INC. | $28.75 | 2025 | Xpovio |
| Recordati_rare_diseases_inc. | $25.52 | 2025 | Enjaymo |
| Morphosys, US INC. | $25.31 | 2023 | Monjuvi |
| Coherus Oncology, INC. | $21.87 | 2025 | Udenyca |
| Taiho Oncology, INC. | $21.43 | 2024 | |
| Emd Serono, INC. | $21.28 | 2025 | |
| Kyowa Kirin, INC. | $18.25 | 2025 | |
| Novocure INC. | $17.74 | 2025 | Optune Lua (Novottf-200t) |
| Apellis Pharmaceuticals, INC. | $17.57 | 2024 | Empaveli |
| Puma Biotechnology, INC. | $16.47 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $16.19 | 2022 | |
| Rigel Pharmaceuticals, INC. | $15.89 | 2022 | |
| Acrotech Biopharma INC. | $13.93 | 2021 | |
| Seagen INC. | $13.77 | 2023 | Padcev |
| Clovis Oncology, INC. | $13.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Atman Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.